In addition, other molecular pathways, such as inhibition of signal transducer and activator of transcription 3/SKP2 axis [31], inhibition of SRC/FAK cue [32], and activation of AMPK et al. [33] have also been involved in the potential anti-HCC effects of statins. Here, STAT3 is linked to hepatocellular carcinoma.